A Randomised, Open-labelled, Active-controlled, Multinational, Dose-escalation Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (NNC0195-0092, Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2018
Price : $35 *
At a glance
- Drugs Somapacitan (Primary) ; Somatrogon
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 18 Apr 2018 Results assessing pooled pharmacokinetic/pharmacodynamic modeling analysis of data from three phase I studies published in the Clinical Pharmacokinetics.
- 04 Apr 2016 Results evaluating suitable dose of Somapacitan in children with growth hormone deficiency presented at The 98th Annual Meeting of the Endocrine Society.